The significant increase in Agile Therapeutics' Q3 net revenue is a positive sign for the company and its investors. The fact that the increase was largely driven by the sales of Twirla indicates that the product is well-received in the market, which could potentially lead to further growth in the future. This is likely to have a positive impact on the company's stock price in the short term.